Intravenous Vitamin C
The potential benefits of Vitamin C based upon clinical studies may include:
- useful as adjuvant therapy for patients with cancer
- enhancement of the effectiveness of chemotherapy
- enhancement in immune functioning
- improved quality of life measures with significant improvement in all areas of function (physical, role, emotional, cognitive and social)
- Improvement of symptoms such as fatigue, nausea/vomiting, pain, insomnia and appetite loss
Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany.
Vollbracht C1, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J.
The aim of the study was to evaluate under praxis conditions the safety and efficacy of intravenous (i.v.) vitamin C administration in the first postoperative year of women with breast cancer.
PATIENTS AND METHODS:
Epidemiological multicentre cohort study, including 15 gynaecologists and general practitioners representatively distributed in Germany. Data from 125 breast cancer patients in UICC stages IIa to IIIb were selected for the study. A total of 53 of these patients were treated with i.v. vitamin C (supplied as Pascorbin® 7.5 g) additional to standard tumour therapy for at least 4 weeks (study group) and 72 without this additional therapy (control group). Main outcome measures were efficacy in regard to outcome and severity of disease- or therapy-induced complaints during adjuvant chemo- and radiotherapy and aftercare.
Comparison of control and study groups revealed that i.v. vitamin C administration resulted in a significant reduction of complaints induced by the disease and chemo-/radiotherapy, in particular of nausea, loss of appetite, fatigue, depression, sleep disorders, dizziness and haemorrhagic diathesis. After adjustment for age and baseline conditions (intensity score before adjuvant therapy, chemotherapy, radiotherapy), the overall intensity score of symptoms during adjuvant therapy and aftercare was nearly twice as high in the control group compared to the study group. No side-effects of the i.v. vitamin C administration were documented.
Oxidative stress and vitamin C deficiency play an important role in the etiology of adverse effects of guideline-based adjuvant chemo-/radiotherapy. Restoring antioxidative capacity by complementary i.v. vitamin C administration helps to prevent or reduce disease-, or therapy-induced complaints in breast cancer patients.
Complementary treatment of breast cancer patients with i.v. vitamin C was shown to be a well tolerated optimization of standard tumour-destructive therapies, reducing quality of life-related side-effects.
According to the Riordan Institute, there are several potential benefits to giving intravenous vitamin C therapy to cancer patients that make it an ideal adjunctive care choice.
Cancer patients are often depleted of vitamin C, and intravenous vitamin Ctherapy provides an efficient means of restoring tissue stores.
intravenous vitamin Ctherapy has been shown to improve quality of life in cancer patients by a variety of metrics.
IVC reduces inflammation (as measured by c-reactive protein levels) and reduces the production of pro-inflammatory cytokines.
At high concentrations, ascorbate is preferentially toxic to tumor cells.
Vitamin C has been shown to make the chemotherapy work better while at the same time improve the quality of life.